Merck Cozaar has 2.5% share of ACE inhibitor market -- Scott-Levin data.
MERCK COZAAR HAS 2.5% SHARE OF ACE INHIBITOR MARKET as of July 14, according to Scott-Levin Associates' Rx Watch. The angiotensin II inhibitor losartan held a 1.4% share of new prescriptions for the month of June, with 22,000 scripts, Scott-Levin reported. The losartan/hydrochlorothiazide combination product Hyzaar held a 1.6% share of the ACE inhibitor/diuretic combo market in June, with 3,000 scripts, Scott-Levin said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth